Rottinghaus Scott T. 4

What Happened

• Scott T. Rottinghaus, Chief Medical Officer of Enanta Pharmaceuticals (ENTA), was issued a total of 6,875 shares on Feb 12, 2026 from performance-based awards (1,650 + 5,225 shares; award price $0). As part of the settlement, 3,413 shares were automatically withheld/disposed to cover withholding taxes, reported at $14.25 per share for a value of $48,635.

Key Details

• Transaction date: February 12, 2026; Form 4 filed February 13, 2026 (timely).
• Awards issued: 1,650 shares (PSUs) and 5,225 shares (rTSRU), both settled in stock at $0 acquisition price.
• Withholding/tax disposition: 3,413 shares withheld at $14.25/share (total $48,635) to satisfy tax obligations.
• Shares owned after transaction: Not disclosed in the filing.
• Transaction codes: A = Award/Grant; F = tax withholding/payment of exercise price.
• Footnotes: PSUs vested based on two-year R&D milestones (2024–2025); rTSRUs vested based on relative total shareholder return vs. Nasdaq Biotech Index over two-year periods; withheld shares represent automatic forfeiture to cover taxes.

Context

• These were performance-vesting awards settled in stock, not open-market purchases or sales. The automatic forfeiture of shares to cover taxes is a common settlement practice and does not necessarily indicate a buy/sell market signal.